Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the PreciseOnco consortium, coordinated by Philips, has been awarded funding from the EU’s Innovative Health Initiative (IHI) to advance precision cancer treatment through the integration of advanced medical imaging, robotic assistance, and minimally invasive therapies. The EUR 14.9 million public funding will be complemented by EUR 9 million in in-kind contributions and additional resources from industry partners, supporting a five-year research and innovation program that also includes five clinical studies.
“Smart imaging and robotic precision are opening new possibilities for minimally invasive cancer treatment,” said Bert van Meurs, Chief Business Leader for Image Guided Therapy at Royal Philips. “By combining spectral imaging, AI-powered software and robotic guidance, we’re developing new solutions to help physicians treat cancer with greater precision, confidence and speed. This leads to better outcomes for patients and a more efficient use of hospital resources. The PreciseOnco partnership brings together technology, clinical expertise and patient perspectives to help improve the way cancer care is delivered.”
Innovation through public-private partnership
Ad Statistics
Times Displayed: 15708
Times Visited: 36 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
The PreciseOnco public-private partnership unites experts from industry, research organizations, medical societies and leading European hospitals:
Industry partners: Philips, Quantum Surgical, and IGEA
Research organization: European Institute for Biomedical Imaging Research (EIBIR)
Medical society: Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Academic partners: University Hospital Cologne (Uniklinik Koeln) in Germany, University Medical Center Utrecht (UMCU) and Leiden University Medical Center (LUMC) in the Netherlands, and two major university hospital networks in France: Assistance Publique–Hôpitaux de Paris (APHP; Hôpital Henri-Mondor) and Hospices Civils de Lyon (HCL)
By uniting Europe’s leading clinical expertise and industry innovation, PreciseOnco aims to set a new benchmark for precision, safety, and efficiency in minimally invasive cancer care.
The rising cancer burden and precision treatment needs
Cancer remains a leading health challenge, with approximately 2.7 million new diagnoses in Europe each year [1] with projections suggesting over 35 million new cancer cases globally by 2050, representing a 77% increase from 2022 [2]. In response to this growing challenge, interventional oncology has emerged as a rapidly evolving discipline that integrates medical imaging, oncology, and minimally invasive treatment approaches [3]. Such treatments – including targeted ablation, radioembolization, and electrochemotherapy – offer advantages over traditional surgery, such as shorter recovery times and fewer side effects; however, their effectiveness strongly depends on the performance of medical imaging and the precision with which physicians can guide instruments to tumors.
